CORPHENA- dexchlorpheniramine maleate solution
BluCrest Pharmaceuticals LLC

CORPHONA
(dexchlorpheniramine maleate) Oral Solution, USP

Rx only

DESCRIPTION

Each 5 mL (teaspoonful) contains:

Dexchlorpheniramine Maleate, USP	2 mg

Dexchlorpheniramine Maleate, USP, an antihistamine agent, is a white, odorless crystalline powder that is freely soluble in water. The molecular formula is $C_{16}H_{19}ClN_2 \cdot C_4H_4O_4$, designated chemically as (+)-2-[p-Chloro-α-[2-(dimethylamino)ethyl]benzyl] pyridine maleate (1:1).



M.W. = 390.86

Inactive Ingredients: Citric acid, cherry flavoring, FD&C Red No. 40, glycerin, menthol, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate dihydrate, and sugar.

CLINICAL PHARMACOLOGY

Dexchlorpheniramine maleate is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.

INDICATIONS AND USAGE

Perennial and seasonal allergic rhinitis

Vasomotor rhinitis

Allergic conjunctivitis due to inhalant allergens and foods

Mild, uncomplicated allergic skin manifestations of urticaria and angioedema

Amelioration of allergic reactions to blood or plasma

Dermographism

As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

CONTRAINDICATIONS

-

Use in Newborn or Premature Infants

This drug should not be used in newborn or premature infants.

Use in Nursing Mothers

Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Use in Lower Respiratory Disease

Antihistamines **should NOT**be used to treat lower respiratory tract symptoms including asthma.

Antihistamines are also contraindicated in the following conditions:
1. Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure
2. Monoamine oxidase inhibitor therapy (See Drug Interactionsection)

WARNINGS

Antihistamines should be used with considerable caution in patients with:
1. Narrow angle glaucoma
2. Stenosing peptic ulcer
3. Pyloroduodenal obstruction
4. Symptomatic prostatic hypertrophy
5. Bladder neck obstruction

Use in Children

In infants and children, especially, antihistamines in **overdosage**may cause hallucinations, convulsions, or death.

As in adults, antihistamines may diminish mental alertness in children. In the young child, particularly, they may produce excitation.

Use in Pregnancy

Experience with this drug in pregnant women is inadequate to determine whether there

exists a potential for harm to the developing fetus.

Use with CNS Depressants

CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).

Use in Activities Requiring Mental Alertness

Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.

Use in the Elderly (approximately 60 years or older)

Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

PRECAUTIONS

CORPHENA Oral Solution has an atropine-like action and, therefore, should be used with caution in patients with:

History of bronchial asthma
Increased intraocular pressure Hyperthyroidism
Cardiovascular disease
Hypertension

Drug Interaction

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

ADVERSE REACTIONS

1. **General:**Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and the throat.
2. **Cardiovascular System:**Hemolytic anemia, thrombocytopenia, agranulocytosis.
3. **Hematologic System:**Hemolytic anemia, thrombocytopenia, agranulocytosis.
4. **Nervous System:**Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesias, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
5. **G.I. System:**Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
6. **G.U. System:**Urinary frequency, difficult urination, urinary retention, early menses.
7. **Respiratory System:**Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

Call your doctor for medical advice about side effects. You may voluntarily report side effects to FDA at 1-800-FDA-1088. Questions or comments? Call BluCrest Pharmaceuticals, LLC at 1-844-700-5011.

OVERDOSAGE

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms—dry mouth, fixed, dilated pupils, flushing, and gastrointestinal symptoms may also occur.

If vomiting has not occurred spontaneously the patient should be induced to vomit. This is best done by having the patient drink a glass of water or milk after which the patient should be made to gag. Precautions against aspiration must be taken, especially in infants and children.

Saline cathartics, such as milk of magnesia, draw water into the bowel by osmosis and therefore, are valuable for their action in rapid dilution of bowel content.

Stimulants should **not** be used.

Vasopressors may be used to treat hypotension.

DOSAGE AND ADMINISTRATION

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

Recommended Dosage

Adults and Children 12 years of age and older: 2 mg (1 teaspoonful)

Children 6 to 11 years: 1 mg (1/2 teaspoonful)

Children 2 to 5 years: 0.5 mg (1/4 teaspoonful)

Doses are generally given every 4 to 6 hours.

HOW SUPPLIED

CORPHENA Oral Solution is supplied as a red colored, cherry flavored liquid in the following sizes:

8 fl oz (237 mL), NDC 73684-300-08

RECOMMENDED STORAGE

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with child-resistant closure.

Rx Only

Manufactured for:

BluCrest Pharmaceuticals, LLC

Hazlet, NJ 07730

www.blucrestpharma.com

Rev. 11/2025

PRINCIPAL DISPLAY PANEL - 237 mL Bottle Label

Keep This and All Medications Out of the Reach of Children.

In Case of Accidental Overdose, Seek Professional Assistance or Contact a Poison Control Center Immediately.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

DO NOT USE IF INNER FOIL SEAL IS BROKEN OR MISSING

NDC 73684-300-08

CORPHENA

(Dexchlorpheniramine Maleate)

Oral Solution, USP

2 mg/5 mL

Cherry Flavor

Rx Only

8 fl. oz (237 mL)

BluCrest PHARMACEUTICALS LLC.

Each 5 mL (teaspoonful) contains:
Dexchlorpheniramine Maleate, USP..... 2 mg

Usual Dosage:
See package insert for full prescribing information.

Pharmacist:
Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure.

Storage:
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured for:
BluCrest Pharmaceuticals, LLC
Hazlet, NJ 07730
www.blucrestpharma.com

Rev. 11/2025

3 73684 30008 8

CORPHENA

dexchlorpheniramine maleate solution

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:73684-300
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
DEXCHLORPHENIRAMINE MALEATE (UNII: B10YD955QW) (DEXCHLORPHENIRAMINE - UNII:3Q9Q0B929N)	DEXCHLORPHENIRAMINE MALEATE	2 mg in 5 mL

Inactive Ingredients

Ingredient Name	Strength
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)	
FD&C RED NO. 40 (UNII: WZB9127XOA)	
GLYCERIN (UNII: PDC6A3C0OX)	
MENTHOL, UNSPECIFIED FORM (UNII: L7T10EIP3A)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
WATER (UNII: 059QF0KO0R)	
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)	
SUCROSE (UNII: C151H8M554)	
CHERRY (UNII: BUC5I9595W)	

Product Characteristics

Color	red	**Score**	
Shape		**Size**	
Flavor	CHERRY	**Imprint Code**	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:73684-300-08	237 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	12/22/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA202520	10/22/2025	

Labeler - BluCrest Pharmaceuticals LLC (117424533)

Revised: 10/2026 BluCrest Pharmaceuticals LLC